TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05289804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NITESGON
Description: NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NITESGON
Description: NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine / Prilocaine Topical Cream
Description: A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C5/C6 stimulation
Description: The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NITESGON
Description: Sham NITESGON
Study: NCT03602898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05887479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Toxin of Clostridium Botulinum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: %0,9 NaCl
Description: %0,9 NaCl
Study: NCT04793555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring by unobtrusive sensors
Description: During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
Study: NCT04719793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-derived Wharton's Jelly
Description: Intraarticular injection
Study: NCT06100042

Intervention type: DRUG
Intervention: BDP/FF/G
Description: BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide).
Study: NCT06476717

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Kidney allograft biopsy

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Kidney allograft biopsy

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Biomarkers - cfDNA
Description: dd-cfDNA

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Biomarkers - cfDNA
Description: dd-cfDNA

Intervention type: DRUG
Intervention: Antirejection therapy
Description: Patients will receive standard antirejection therapy according to center protocol.
Study: NCT03602898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05218005

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Research-based genetic test for Familial Hypercholesterolemia
Description: Next-generation targeted sequencing assay to identify DNA variants in genes known to cause Familial Hypercholesterolemia
Study: NCT05295498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation
Description: High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham stimulation to mimic the high frequency rTMS over the primary motor area.
Study: NCT04826393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: every 3 weeks by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: every 3 weeks by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: intravenous infusion
Study: NCT06195553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPPS plus Family Connections
Description: The intervention will be based on cognitive and behavior treatment using STEPPS for the patients and dialectical and behavior treatment using Family Connections for the families. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Main components Family Connections: psychoeducation, skills training and peer support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEPPS
Description: The intervention will be based on cognitive and behavior treatment using STEPPS for the patients. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Waiting list group: Participant's relatives of this group will be able to receive the Family Connections intervention after the research end.
Study: NCT06669429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single ascending dose
Study: NCT06219902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration of multiple doses of elinzanetant.
Study: NCT06669429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single ascending dose
Study: NCT03602898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT06669429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a multiple ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a multiple ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a multiple ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
Study: NCT03602898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplantation
Study: NCT06669429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
Study: NCT03602898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplantation
Study: NCT06219902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration of multiple doses of elinzanetant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration of multiple doses of elinzanetant.
Study: NCT03602898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT03602898

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT05332626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10\^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
Study: NCT06669429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
Study: NCT05695235

Intervention type: DEVICE
Intervention: CGM
Description: Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.

Intervention type: DEVICE
Intervention: CGM
Description: Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.

Intervention type: DEVICE
Intervention: Oura ring
Description: Wearable sleep tracking device

Intervention type: DEVICE
Intervention: Oura ring
Description: Wearable sleep tracking device
Study: NCT06219902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration of multiple doses of elinzanetant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to elinzanetant
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to elinzanetant
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to elinzanetant
Description: Oral administration
Study: NCT05695235

Intervention type: BEHAVIORAL
Intervention: Cognitive tasks and questionnaires
Description: Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
Study: NCT06219902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to elinzanetant
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Oral administration
Study: NCT06219902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zopiclone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zopiclone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zopiclone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zopiclone
Description: Oral administration
Study: NCT05194631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps microbiopsy using a Tru-Cut biopsy needle
Description: During surgery for a benign or malignant tumor of the liver a quadriceps microbiopsy will be performed. A 1 cm incision of the skin and fat planes will be made using a scalpel until contact with the quadriceps aponeurosis. The biopsy needle will be inserted superficially into the muscular part allowing, through a suction system, a micro biopsy of the quadriceps of approximately 25 mg.
Study: NCT06669429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
Study: NCT05904873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Third Molar Surgery
Description: All surgical procedures were carried out by a single dental(maxillofacial) surgeon different from the clinician performing the cold testing. A total of 4 cc of local anesthetic solution containing 40 mg/ml articaine and 0.005 mg/ml epinephrine was applied to the inferior alveolar and buccal nerve blocks before the surgical procedure. In all cases, the mucoperiosteal flap was raised and bone was removed from the buccal and distal parts of the impacted tooth with burs, while protecting the papilla between the first and second molars during flap design. Before extraction, if necessary, the third molar was divided and tooth extraction was performed with elevators. The flap was brought to its original position and closed with silk suture material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Third Molar Surgery
Description: All surgical procedures were carried out by a single dental(maxillofacial) surgeon different from the clinician performing the cold testing. A total of 4 cc of local anesthetic solution containing 40 mg/ml articaine and 0.005 mg/ml epinephrine was applied to the inferior alveolar and buccal nerve blocks before the surgical procedure. In all cases, the mucoperiosteal flap was raised and bone was removed from the buccal and distal parts of the impacted tooth with burs, while protecting the papilla between the first and second molars during flap design. Before extraction, if necessary, the third molar was divided and tooth extraction was performed with elevators. The flap was brought to its original position and closed with silk suture material.
Study: NCT04766892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules
Study: NCT05129501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Tiwahe Wicagwicayapi seven-session program is for children ages 10 to 14 who are Native American and/or living in poverty and their caregivers. The program begins with a traditional Lakota meal followed by family time and break-out time for caregivers only and children only. The program includes skill-building activities as well as the integration of Lakota language, history, and culture. The program is facilitated by diverse individuals, predominantly Native Americans in Rapid City and surrounding tribal communities.
Study: NCT06669429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
Study: NCT06669793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biolimus-coated balloon
Description: 238 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Biolimus-coated balloon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-coated balloon
Description: 237 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of paclitaxel-coated balloon.
Study: NCT06669988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR
Description: VR - Immersive instruction using virtual reality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video
Description: Video - Educational content presented through video.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: written materials
Description: Written Materials - Instruction using text and images.
Study: NCT06613347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whitening maintenance
Description: whitening maintenance regimen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whitening maintenance MW
Description: maintenance MW

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: negative control
Description: negative control
Study: NCT06670807

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Arm
Description: Fifty of the participants will consume 1 capsule/day of the dietary supplement AB-MIND+CECT7481 for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the intervention period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifty of the participants will consume 1 capsule/day of the PLACEBO for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the entire intervention period.
Study: NCT05316103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy targeted optical biopsy
Description: After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
Study: NCT04993781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSTEPS CDS
Description: Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.